FI20031528A0 - Terapeuttinen liposomikoostumus ja menetelmä sen valmistamiseksi - Google Patents

Terapeuttinen liposomikoostumus ja menetelmä sen valmistamiseksi

Info

Publication number
FI20031528A0
FI20031528A0 FI20031528A FI20031528A FI20031528A0 FI 20031528 A0 FI20031528 A0 FI 20031528A0 FI 20031528 A FI20031528 A FI 20031528A FI 20031528 A FI20031528 A FI 20031528A FI 20031528 A0 FI20031528 A0 FI 20031528A0
Authority
FI
Finland
Prior art keywords
preparation
liposome composition
therapeutic liposome
therapeutic
composition
Prior art date
Application number
FI20031528A
Other languages
English (en)
Swedish (sv)
Inventor
Ying Zhu
Heli Valtanen
Sami Kaukinen
Medina Oula Penate
Original Assignee
Ctt Cancer Targeting Tech Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ctt Cancer Targeting Tech Oy filed Critical Ctt Cancer Targeting Tech Oy
Priority to FI20031528A priority Critical patent/FI20031528A0/fi
Publication of FI20031528A0 publication Critical patent/FI20031528A0/fi
Priority to JP2006534777A priority patent/JP2008505049A/ja
Priority to CA002542684A priority patent/CA2542684A1/en
Priority to US10/576,086 priority patent/US20070140972A1/en
Priority to EP04791442A priority patent/EP1685153A1/en
Priority to PCT/FI2004/050150 priority patent/WO2005037862A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
FI20031528A 2003-10-17 2003-10-17 Terapeuttinen liposomikoostumus ja menetelmä sen valmistamiseksi FI20031528A0 (fi)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FI20031528A FI20031528A0 (fi) 2003-10-17 2003-10-17 Terapeuttinen liposomikoostumus ja menetelmä sen valmistamiseksi
JP2006534777A JP2008505049A (ja) 2003-10-17 2004-10-15 ターゲティング組成物及びその製造方法
CA002542684A CA2542684A1 (en) 2003-10-17 2004-10-15 Targeting compositions and preparation thereof
US10/576,086 US20070140972A1 (en) 2003-10-17 2004-10-15 Targeting compositions and preparation therof
EP04791442A EP1685153A1 (en) 2003-10-17 2004-10-15 Targeting compositions and preparation thereof
PCT/FI2004/050150 WO2005037862A1 (en) 2003-10-17 2004-10-15 Targeting compositions and preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20031528A FI20031528A0 (fi) 2003-10-17 2003-10-17 Terapeuttinen liposomikoostumus ja menetelmä sen valmistamiseksi

Publications (1)

Publication Number Publication Date
FI20031528A0 true FI20031528A0 (fi) 2003-10-17

Family

ID=29225968

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20031528A FI20031528A0 (fi) 2003-10-17 2003-10-17 Terapeuttinen liposomikoostumus ja menetelmä sen valmistamiseksi

Country Status (6)

Country Link
US (1) US20070140972A1 (fi)
EP (1) EP1685153A1 (fi)
JP (1) JP2008505049A (fi)
CA (1) CA2542684A1 (fi)
FI (1) FI20031528A0 (fi)
WO (1) WO2005037862A1 (fi)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
EP1587944A4 (en) 2002-03-01 2007-03-21 Dyax Corp KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
FI20040682A0 (fi) * 2004-05-14 2004-05-14 Ctt Cancer Targeting Tech Oy Tuumorien ja mestastaasien kuvantaminen käyttäen gelatinaasiin targetoituvaa peptidiä
FI20050695A0 (fi) * 2005-06-30 2005-06-30 Ctt Cancer Targeting Tech Oy Menetelmä fosfolipidi-PEG-biomolekyyli-konjugaattien valmistamiseksi
CA2631716C (en) * 2005-12-09 2013-11-26 Bracco International B.V. Targeting vector-phospholipid conjugates
WO2007149433A2 (en) 2006-06-19 2007-12-27 The Johns Hopkins University Tumor-specific delivery of therapeutic agents via liposomase
WO2009038779A2 (en) * 2007-09-19 2009-03-26 University Of Tennessee Research Foundation Methods and compositions for inhibiting undesirable cellular proliferation by targeted liposome delivery of active agents
JP2012510477A (ja) 2008-12-02 2012-05-10 ザ ユニバーシティー オブ メルボルン 放射性医用薬剤としての窒素含有大環状結合体
EP2556085A2 (en) * 2010-04-05 2013-02-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
US8871189B2 (en) 2011-11-30 2014-10-28 Mallinckrodt Llc MMP-targeted therapeutic and/or diagnostic nanocarriers
AU2012350147B2 (en) 2011-12-06 2017-08-03 Clarity Pharmaceuticals Ltd Cage amine ligands for metallo-radiopharmaceuticals
ITUB20160191A1 (it) * 2016-01-21 2017-07-21 Invectors S R L Kit per la preparazione di doxorubicina liposomiale funzionalizzata con peptidi per il target selettivo di recettori sovra espressi da cellule tumorali
JP2017098216A (ja) * 2016-06-28 2017-06-01 住友化学株式会社 非水電解液二次電池用絶縁性多孔質層および非水電解液二次電池用積層セパレータ

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI113840B (fi) * 2001-03-26 2004-06-30 Ctt Cancer Targeting Tech Oy Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa
FI20021726A0 (fi) * 2002-09-27 2002-09-27 Ctt Cancer Targeting Tech Oy Menetelmä peptidien tuottamiseksi

Also Published As

Publication number Publication date
WO2005037862A1 (en) 2005-04-28
US20070140972A1 (en) 2007-06-21
EP1685153A1 (en) 2006-08-02
CA2542684A1 (en) 2005-04-28
JP2008505049A (ja) 2008-02-21

Similar Documents

Publication Publication Date Title
NO20030418L (no) Nytt farmasöytisk preparat
NO20033143D0 (no) Farmasoytisk preparat
EE05104B1 (et) Asetidiini derivaadid, nende valmistamise meetodid ja farmatseutiline kompositsioon
IL173808A0 (en) Pharmaceutical liposomal formulations
DK1620118T3 (da) Reversible pegylerede lægemidler
NO20050132D0 (no) Vaksinesammensetning
DK1524266T3 (da) Farmaceutisk sammensætning
FI20011478A (fi) Farmaseuttinen koostumus
FI20031528A0 (fi) Terapeuttinen liposomikoostumus ja menetelmä sen valmistamiseksi
DK1587478T3 (da) Farmaceutisk sammensætning
IL165661A0 (en) Liposomal vaccine
EP1522316A4 (en) TRANSDERMAL ABSORPTION PREPARATION
ATE421875T1 (de) Superfeine salmeterol zubereitung
NO20025805D0 (no) Farmasöytisk preparat
PT1558263E (pt) Composicao farmaceutica de libertacao prolongada
EP1652523A4 (en) PREPARATION FOR TRANSDERMAL ABSORPTION
FI20041675A0 (fi) Katalyyttiset materiaalit ja menetelmä niiden valmistamiseksi
HK1100424A1 (en) Oral preparations and process for production thereof
PT1603550E (pt) Composição farmacêutica que compreende ácido 5-metil-2-2¿- (cloro-6¿-fluoroanilino)fenilacético
ATE546141T1 (de) Pharmazeutisches injektionspräparat
FI20050371A (fi) Sementti-betoniseos, menetelmä sen valmistamiseksi ja menetelm kiveystuotteiden valmistamiseksi
FI20041616A0 (fi) Uudet polymeerit ja menetelmä niiden valmistamiseksi
FI20030044A (fi) Lääkeannostelijan toiminnan ohjausmenetelmä ja mekanismi sen toteuttamiseksi
IS7581A (is) Lyfjasamsetning
FI20030733A (fi) Menetelmä ja sovitelma betonituotteen valmistamiseksi

Legal Events

Date Code Title Description
FD Application lapsed

Free format text: IPSEN MANUFACTURING IRELAND LIMITED